LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

Genomic alterations of BRAF are common oncogenic drivers in pediatric low-grade glioma (pLGG). Tovorafenib is an investigational, oral, selective, brain-penetrant, small molecule, type II panRAF inhibitor. FIREFLY-1 (NCT04775485) is a multicenter phase 2 study evaluating the efficacy and safety of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilburn, Lindsay, Khuong-Quang, Dong-Anh, Nysom, Karsten, Landi, Daniel, Ziegler, David, Driever, Pablo Hernáiz, Leary, Sarah, Bailey, Simon, Van der Lugt, Jasper, Perreault, Sebastien, Waanders, Angela, Baxter, Patricia, Witt, Olaf, Hargrave, Darren, McCowage, Geoffrey, Zhao, Xin, Da Costa, Daniel, Cox, Michael, Manley, Peter, Hansford, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Low Grade Gliomas - LGG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260080/
http://dx.doi.org/10.1093/neuonc/noad073.219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260080/
http://dx.doi.org/10.1093/neuonc/noad073.219

Ejemplares similares